Sarah R. Leist

The paper investigates how IGHV3-53/3-66 antibodies from Omicron BA.1 infection neutralize emerging SARS-CoV-2 variants through structural and mutational analysis.

The paper identifies immune mediators linking host susceptibility loci to disease severity across SARS-CoV and SARS-CoV-2 infections.

This paper develops a mouse model of SARS-CoV-2 BA.5 infection that induces fibrotic lung disease and tertiary lymphoid structures, enabling study of acute and post-acute sequelae of COVID-19.

This study uses multi-omics analysis to show that dysregulated lung epithelial cell homeostasis and immune responses drive severe MERS-CoV disease in mice.

This study compares IgG antibody responses from SARS-CoV-2 infection, vaccination, and hybrid immunity, finding that hybrid immunity retains the imprint of the initial exposure and enhances antibody breadth and affinity.

The paper identifies a genetic locus associated with coronavirus disease susceptibility in mice and shows its relevance to human severe COVID-19 outcomes.

This paper demonstrates that MM3122, a host cell serine protease inhibitor, effectively inhibits SARS-CoV-2 replication and reduces disease severity in mice, both prophylactically and therapeutically.

This study shows that MA10 SARS-CoV-2 infection in mice leads to neuropathological changes in the hippocampus, mirroring the prevalence of Long COVID in humans.

The paper uses CRISPR screens to identify mucins as key host factors that restrict SARS-CoV-2 infection in human lung cells.